Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ai |
RCV000024511 | SCV002502540 | uncertain significance | not provided | 2021-10-20 | criteria provided, single submitter | clinical testing | |
MGZ Medical Genetics Center | RCV002288520 | SCV002580862 | pathogenic | MYPN-related myopathy | 2022-05-25 | criteria provided, single submitter | clinical testing | |
Invitae | RCV003764634 | SCV004611247 | pathogenic | Dilated cardiomyopathy 1KK | 2023-10-04 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg885*) in the MYPN gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MYPN are known to be pathogenic (PMID: 28017374). This variant is present in population databases (rs199476412, gnomAD 0.006%). This premature translational stop signal has been observed in individual(s) with autosomal recessive congenital myopathy and autosomal dominant hypertrophic cardiomyopathy (PMID: 28220527). ClinVar contains an entry for this variant (Variation ID: 31818). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Muscle and Diseases Team, |
RCV004586025 | SCV005038577 | pathogenic | Cap myopathy | 2024-03-01 | criteria provided, single submitter | research | PVS1+PS3+PM2+PP3+PP4+PP5 |
Ambry Genetics | RCV004639122 | SCV005146179 | pathogenic | Cardiovascular phenotype | 2024-05-16 | criteria provided, single submitter | clinical testing | The p.R885* pathogenic mutation (also known as c.2653C>T), located in coding exon 11 of the MYPN gene, results from a C to T substitution at nucleotide position 2653. This changes the amino acid from an arginine to a stop codon within coding exon 11. This variant has been identified in the homozygous state in two individual(s) from one family with features consistent with MYPN-related nemaline myopathy (Lornage X et al. Ann Neurol, 2017 Mar;81:467-473). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Leiden Muscular Dystrophy |
RCV000024511 | SCV000045815 | not provided | not provided | 2012-04-27 | no assertion provided | curation |